Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Uncover phase 2 clinical trial results of CagriSema, a promising diabetes treatment showing improvements in A1C, weight loss, and time in range.
Pfizer propels clinical trials for danuglipron, a novel oral GLP-1 medication for obesity and type 2 diabetes, with promising preliminary results for A1C and weight loss.
Explore the role of artificial intelligence in diabetic retinopathy detection with Eyenuk's innovative technology. Here we also examine the disputed effects of GLP-1s on...
New research reveals a higher dementia risk in early-onset diabetes. Preventing prediabetes progression may be key to mitigating this risk.
At the 17th annual Diabetes Forum at ADA 2023, the diaTribe Foundation and TCOYD moderated an expert panel that discussed access and equity issues, breakthrough...
A lot has happened this year advancing time in range as a primary glucose metric in diabetes care globally. Though we aren’t there yet, a panel shared their thoughts on...
Clinical trial participants taking retatrutide for obesity experienced an average of 24% in body weight reduction over 48 weeks. Lead scientists shared their findings at...
PIONEER PLUS and OASIS 1 trials show high-dose Rybelsus significantly reduces A1C and promotes weight loss in type 2 diabetes and obesity patients.
Clinical trial results have shown that once-weekly basal insulins are just as effective at reducing A1C as once-daily insulin.
Results from a recent clinical trial showed the new medication survodutide may be a useful treatment tool for weight loss. People with overweight or obesity on the...
On the search for a type 1 diabetes cure, scientists are experimenting with how to engineer beta cells to survive immune system attacks. At the American Diabetes...
People with type 1 and 2 diabetes report experiencing diabetes stigma regardless of which devices they use. But when we start looking at which groups report the most...
end Uncover SURMOUNT-2 trial's outcomes: Tirzepatide's promise for weight loss, better blood sugar, and improved cardiometabolic health in type 2 diabetes.
New drug treatments are now available for children with diabetes following the recent approval of Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin...
Join diaTribe at the American Diabetes Association's 83rd scientific conference for insights on future diabetes care, medication, and the latest tech. Plus, explore...
Early screening for type 1 diabetes is vital for timely treatment and prevention of certain complications. With recent advancements such as the FDA approval of Tzield (...
Explore groundbreaking research that connects type 2 diabetes and Alzheimer's disease through mitochondrial dysfunction. The link unveils new insights in elder care and...
New findings from the DiRECT trial reveal that weight loss can lead to type 2 diabetes remission. Learn about the benefits of a low-calorie diet and support in diabetes...
Reduce heart failure risk with FDA-approved Inpefa (sotagliflozin). Inhibiting SGLT-2 and SGLT-1, it outshines other medications. Learn more about its effectiveness and...
In case you missed them, here are our top stories from May 2023. This month’s best stories cover a wide variety of topics like upcoming therapies, new research findings...

Pages